MX2014011646A - Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos. - Google Patents

Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos.

Info

Publication number
MX2014011646A
MX2014011646A MX2014011646A MX2014011646A MX2014011646A MX 2014011646 A MX2014011646 A MX 2014011646A MX 2014011646 A MX2014011646 A MX 2014011646A MX 2014011646 A MX2014011646 A MX 2014011646A MX 2014011646 A MX2014011646 A MX 2014011646A
Authority
MX
Mexico
Prior art keywords
hcmv
idiotypic antibodies
idiotypic
antibodies
methods
Prior art date
Application number
MX2014011646A
Other languages
English (en)
Inventor
Jo-Anne Hongo
Rajesh Vij
Keyang Xu
Mauricio Maia
Terrence Wong
John Lowe
Yanhong Li
Luna Liu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014011646A publication Critical patent/MX2014011646A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona anticuerpos antiidiotipo HCMV y métodos para utilizarlos.
MX2014011646A 2012-03-28 2013-03-15 Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos. MX2014011646A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616914P 2012-03-28 2012-03-28
PCT/US2013/032661 WO2013148373A1 (en) 2012-03-28 2013-03-15 Anti-hcmv idiotypic antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2014011646A true MX2014011646A (es) 2015-02-24

Family

ID=48087712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011646A MX2014011646A (es) 2012-03-28 2013-03-15 Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos.

Country Status (12)

Country Link
US (2) US9139659B2 (es)
EP (1) EP2831119A1 (es)
JP (1) JP2015518471A (es)
KR (1) KR20140138971A (es)
CN (1) CN104334583A (es)
AR (1) AR090510A1 (es)
BR (1) BR112014024023A2 (es)
CA (1) CA2868161A1 (es)
HK (1) HK1206759A1 (es)
MX (1) MX2014011646A (es)
RU (1) RU2014143251A (es)
WO (1) WO2013148373A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909174A1 (en) * 2012-10-19 2015-08-26 F. Hoffmann-La Roche AG Inhibitors of syk
WO2018119474A2 (en) * 2016-12-23 2018-06-28 Remd Biotherapeutics, Inc. Immunotherapy using antibodies that bind programmed death 1 (pd-1)
WO2018136553A1 (en) * 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
KR102344616B1 (ko) * 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 항-더블코르틴-유사 키나제 1 항체 및 사용 방법
US12084514B2 (en) 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
CN112899235B (zh) * 2019-12-03 2024-06-21 夏尔巴生物技术(苏州)有限公司 一种细胞培养液的收获方法
TW202314247A (zh) * 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) * 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) * 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4536479A (en) * 1983-03-22 1985-08-20 E. I. Du Pont De Nemours And Company Use of anti-idiotype antibodies in immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6020208A (en) 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
JP2004532392A (ja) 2001-02-20 2004-10-21 アドヴィオン バイオサイエンシィズ インコーポレイテッド 親和性吸着剤を有するマイクロチップ電子噴霧装置およびカラムならびにそれらの使用法
US20080268459A1 (en) * 2003-08-14 2008-10-30 Wyeth Ludwig Institute For Cancer Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof
EP2037959B1 (en) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ATE503769T1 (de) 2006-12-15 2011-04-15 Ribovax Biotechnologies Sa Antikörper gegen das humane cytomegalie-virus (hcmv)
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141432A1 (es) * 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
EA201270662A1 (ru) * 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
EA201390467A1 (ru) * 2010-09-29 2013-11-29 Дженентек, Инк. Композиции антител и способы применения
EP2793941A1 (en) * 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies

Also Published As

Publication number Publication date
WO2013148373A1 (en) 2013-10-03
US20130266973A1 (en) 2013-10-10
HK1206759A1 (en) 2016-01-15
EP2831119A1 (en) 2015-02-04
US20160002355A1 (en) 2016-01-07
KR20140138971A (ko) 2014-12-04
CA2868161A1 (en) 2013-10-03
CN104334583A (zh) 2015-02-04
US9139659B2 (en) 2015-09-22
JP2015518471A (ja) 2015-07-02
BR112014024023A2 (pt) 2017-07-18
AR090510A1 (es) 2014-11-19
WO2013148373A8 (en) 2014-09-25
RU2014143251A (ru) 2016-05-20

Similar Documents

Publication Publication Date Title
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
MX2022000026A (es) Anticuerpos para tau.
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2014011646A (es) Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2019006902A (es) Inmunoglobulinas heterodimericas.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
EP2892562A4 (en) ANTI-MCAM ANTIBODIES AND ASSOCIATED METHOD FOR USE
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
IN2015DN00127A (es)
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
IN2014DN09450A (es)
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.